Fig. 3. SF1126 inhibits Akt-mTOR and BRD4 signalings in CRC cells. HT-29 cells (A-F) or primary human colon cancer cells ("pri-Can-1/2", G and H) were treated with applied concentrations (0.2-10 μM) of SF1126. Cells were further cultured for the indicated times, and the expression of the listed mRNA and proteins in total cell lysates were tested by qPCR and Western blotting assays, respectively. The total gray area in each band was quantified and normalized to tubulin (F-H). *p< 0.05 vs. the "C" group (D and E). The experiments were repeated three times, with similar results obtained.